BR112012013497A2 - geração em larga escala de megacariócitos e plaquetas funcionais a partir de células-tronco embrionárias humanas sob condições livres de estroma - Google Patents

geração em larga escala de megacariócitos e plaquetas funcionais a partir de células-tronco embrionárias humanas sob condições livres de estroma

Info

Publication number
BR112012013497A2
BR112012013497A2 BR112012013497A BR112012013497A BR112012013497A2 BR 112012013497 A2 BR112012013497 A2 BR 112012013497A2 BR 112012013497 A BR112012013497 A BR 112012013497A BR 112012013497 A BR112012013497 A BR 112012013497A BR 112012013497 A2 BR112012013497 A2 BR 112012013497A2
Authority
BR
Brazil
Prior art keywords
platelets
megakaryocytes
stem cells
embryonic stem
human embryonic
Prior art date
Application number
BR112012013497A
Other languages
English (en)
Inventor
Feng Li
Shi-Jiang Lu
Original Assignee
Stem Cell & Regenerative Medicine International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stem Cell & Regenerative Medicine International Inc filed Critical Stem Cell & Regenerative Medicine International Inc
Publication of BR112012013497A2 publication Critical patent/BR112012013497A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2311—Interleukin-11 (IL-11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1394—Bone marrow stromal cells; whole marrow
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

geração em larga escala de megacariócitos e plaquetas funcionais a partir de células-tronco embrionárias humanas sob condições livres de estroma. a presente invenção provê um método para geração de megacariócitos e plaquetas. em várias modalidades, o método envolve o uso de células-tronco embrionárias humanas derivadas de hemangioblastos para diferenciação em megacariócitos e plaquetas sob condição livre do soro e estroma. nesse sistema, as ctehs são conduzidas em direção a megacariócitos através de formação de corpo embrioide e diferenciação de hemangioblasto. é adicionalmente provido um método para tratamento de um sujeito necessitando de transfusão de plaquetas.
BR112012013497A 2009-12-04 2010-12-03 geração em larga escala de megacariócitos e plaquetas funcionais a partir de células-tronco embrionárias humanas sob condições livres de estroma BR112012013497A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26693909P 2009-12-04 2009-12-04
US38416510P 2010-09-17 2010-09-17
PCT/US2010/058990 WO2011069127A1 (en) 2009-12-04 2010-12-03 Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions

Publications (1)

Publication Number Publication Date
BR112012013497A2 true BR112012013497A2 (pt) 2016-05-31

Family

ID=44115332

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013497A BR112012013497A2 (pt) 2009-12-04 2010-12-03 geração em larga escala de megacariócitos e plaquetas funcionais a partir de células-tronco embrionárias humanas sob condições livres de estroma

Country Status (10)

Country Link
US (2) US9988603B2 (pt)
EP (1) EP2507359A4 (pt)
JP (4) JP2013512676A (pt)
KR (4) KR20190142424A (pt)
AU (4) AU2010325811A1 (pt)
BR (1) BR112012013497A2 (pt)
CA (2) CA2782013C (pt)
IN (1) IN2012DN05054A (pt)
RU (1) RU2012127810A (pt)
WO (1) WO2011069127A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5630781B2 (ja) 2006-04-14 2014-11-26 アドバンスド セル テクノロジー、インコーポレイテッド 血管コロニー形成細胞
KR20190142424A (ko) 2009-12-04 2019-12-26 스템 셀 앤드 리제너러티브 메디신 인터내셔날, 인크. 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성
GB201210857D0 (en) 2012-06-19 2012-08-01 Cambridge Entpr Ltd Transcription factor mediated programming towards megakaryocytes
ES2896354T3 (es) * 2012-12-21 2022-02-24 Astellas Inst For Regenerative Medicine Métodos para la producción de plaquetas a partir de células madre pluripotentes
JP6580329B2 (ja) 2014-03-31 2019-09-25 シスメックス株式会社 未分化細胞から分化細胞および／または分化細胞の産生物を取得する方法
US10538738B2 (en) 2014-05-19 2020-01-21 Eleftherios Papoutsakis Megakaryocytic particles and microparticles for cell therapy and fate modification of stem and progenitor cells
AU2016242823A1 (en) * 2015-03-30 2017-09-21 Jeffrey Thomas Loh Methods for producing modified red blood cell compositions, compositions and uses thereof
KR20230058544A (ko) 2015-08-18 2023-05-03 아스텔라스 인스티튜트 포 리제너러티브 메디슨 임상 제제
RU2766177C2 (ru) * 2015-10-14 2022-02-08 Мегакарион Корпорейшн Способ получения очищенных тромбоцитов

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128259A (en) 1989-10-27 1992-07-07 Hahnemann University Factor-dependent hematopoietic cell line exhibiting epo-induced erythrocyte maturation
EP1364197B1 (en) 2001-01-29 2010-04-14 Ivan N. Rich ATP-based assay for the determination of the proliferation status of hematopoietic stem and progenitor cells
WO2002078449A2 (en) 2001-04-02 2002-10-10 Advanced Cell Technology, Inc. Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells
EP1456374A4 (en) 2001-11-26 2005-08-17 Advanced Cell Tech Inc METHODS FOR THE PRODUCTION AND USE OF REPROGRAMME HUMAN SOMATIC CELL CORES AND AUTOLOGOUS AND ISOGENIC HUMAN STEM CELLS
US20040052771A1 (en) 2002-07-12 2004-03-18 Lim Sai Kiang Hemangioblast progenitor cells
US20040229350A1 (en) 2003-05-12 2004-11-18 Nikolai Strelchenko Morula derived embryonic stem cells
CN1286970C (zh) 2003-12-30 2006-11-29 上海伯瑞生物技术发展有限公司 由脐血cd34+细胞体外诱导生成巨核细胞的方法
US20050221482A1 (en) 2004-03-31 2005-10-06 Burt Richard K Methods and compositions for obtaining hematopoietic stem cells derived from embryonic stem cells and uses thereof
US20060099198A1 (en) * 2004-11-01 2006-05-11 Thomson James A Platelets from stem cells
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
AU2007215276B2 (en) 2006-02-09 2013-09-19 Maryna E. Gumenyuk Erythroid cells producing adult-type beta-hemoglobin generated from human embryonic stem cells
CN101045914A (zh) 2006-03-29 2007-10-03 中国人民解放军军事医学科学院野战输血研究所 体外诱导造血干/祖细胞分化为成熟红细胞的方法与应用
JP5630781B2 (ja) 2006-04-14 2014-11-26 アドバンスド セル テクノロジー、インコーポレイテッド 血管コロニー形成細胞
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9683232B2 (en) * 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
US9410123B2 (en) 2008-05-06 2016-08-09 Ocata Therapeutics, Inc. Hemangio colony forming cells and non-engrafting hemangio cells
KR101803562B1 (ko) 2008-05-06 2017-12-01 아스텔라스 인스티튜트 포 리제너러티브 메디슨 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법
KR20190142424A (ko) 2009-12-04 2019-12-26 스템 셀 앤드 리제너러티브 메디신 인터내셔날, 인크. 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성

Also Published As

Publication number Publication date
KR20120128605A (ko) 2012-11-27
RU2012127810A (ru) 2014-01-10
AU2017201995B2 (en) 2019-06-06
AU2019203670A1 (en) 2019-06-13
IN2012DN05054A (pt) 2015-10-09
KR20210066020A (ko) 2021-06-04
WO2011069127A1 (en) 2011-06-09
JP2022064953A (ja) 2022-04-26
KR20180086301A (ko) 2018-07-30
AU2017201995A1 (en) 2017-04-13
EP2507359A4 (en) 2015-05-13
US20120315338A1 (en) 2012-12-13
JP2019122385A (ja) 2019-07-25
AU2019203670B2 (en) 2021-10-14
US20190002829A1 (en) 2019-01-03
JP2013512676A (ja) 2013-04-18
AU2022200188A1 (en) 2022-02-10
CA2782013A1 (en) 2011-06-09
JP2016135138A (ja) 2016-07-28
CA3115233A1 (en) 2011-06-09
KR20190142424A (ko) 2019-12-26
EP2507359A1 (en) 2012-10-10
CA2782013C (en) 2021-06-08
AU2010325811A1 (en) 2012-06-21
US9988603B2 (en) 2018-06-05

Similar Documents

Publication Publication Date Title
BR112012013497A2 (pt) geração em larga escala de megacariócitos e plaquetas funcionais a partir de células-tronco embrionárias humanas sob condições livres de estroma
HN2012001223A (es) Antagonistas de pcsk 9
TR201807912T4 (tr) Seçi̇ci̇ sfi̇ngozi̇n 1 fosfat reseptör düzenleyi̇ci̇leri̇ ve ki̇ral sentez yöntemleri̇.
BR112012010321B8 (pt) válvula de substituição para uso em um corpo humano
CR20120668A (es) Procedimiento para la producción selectiva de hidrocarburos a partir de algas utilizando agua en condiciones subcríticas
WO2012100093A3 (en) Biorefinery system, components therefor, methods of use, and products derived therefrom
BR112015010409A2 (pt) dispositivo para controlar o fluxo de gás a partir de um recipiente de gás, e, método para controlar o fluxo de gás a partir de um recipiente de gás
TWD174791S (zh) 氣流產生器
BR112012010136A2 (pt) células -tronco pluripotentes
BR112015006100A2 (pt) microcápsulas produzidas por secagem por atomização
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
BR112012005835A2 (pt) alteração da temperatura em um corpo de mamífero
BR112015005878A2 (pt) nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas
BR112014010900A2 (pt) métodos de preparar sistema de catalisador
CR20110526A (es) Anticuerpos anti - tnf - alfa y sus usos
BR112013000598A2 (pt) artigo absorvente para vestir em duas peças com configurações de desempenho de fecho vantajosas
BRPI1011564A8 (pt) Fio de material de sutura cirúrgica, kit cirúrgico e método para produzir fio
CL2012000768A1 (es) Compuestos derivados de acido l-glutamico y l-glutamina marcados con [18f]; procedimiento de preparacion; y su uso para el diagnostico de enfermedades tumorales.
BR112014011381A2 (pt) artigos absorventes com sistemas de fixação por gancho e laço
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
RS53408B (en) PHARMACEUTICAL COMPOSITION OF IBUPROFEN FOR INJECTION
AR064219A1 (es) Cuerpo moldeado que contiene titanio
GR1006881B (el) Αντιγηραντικες ιδιοτητες της κερκετινης, του 18(α) - γλυκυρετινικου οξεος της χεδεραγενινης και των παραγωγων τους
BR112012029645A2 (pt) válvula projetada para indicar a passagem ou não de um fluido

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]